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PATIENT CHARACTERISTICS
Total Unmanipulated TNC/kg x 10^7 6.2 (4.3 to 17)
Total Unmanipulated CD34/kg x 10^6 0.3 (0.09 to 1)
Expanded Product TNC/kg x 10^7 5.8 (2.2 to 10)
Expanded Product CD34/kg x 10^6 6 (3.1 to 11)
*HLA matching reflects the lowest HLA-match of the 2 unmanipulated
units.4
INFUSION OF NON-HLA MATCHED, OFF-THE-SHELF EX VIVO EXPANDED
CORD BLOOD PROGENITOR CELLS IN PATIENTS UNDERGOING MYELOA-
BLATIVE CORDBLOOD TRANSPLANTATION IS SAFE AND DECREASES THE
TIME TO NEUTROPHIL RECOVERY
Delaney, C.1,2, Milano, F.1, Shelly, H.1, Nicoud, I.1, Bernstein, I.D.1,2
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of
Washington School of Medicine, Seattle, WA
With the goal of overcoming the significant delay in ANC re-
covery following cord blood transplantation (CBT), we have de-
veloped a clinically feasible methodology utilizing Notch ligand
for ex vivo generation of increased numbers of CD34+ cells.
Having previously demonstrated a significant reduction in ANC
recovery time in patients receiving these partially HLA-matched
expanded cells in a myeloablative CBT, we are now evaluating
whether this product could also support rapid myeloid recovery
when used as a non-HLA matched, off-the-shelf product. In
this new pilot study, patients undergo single or double ablative
CBT plus infusion of progenitors that have been previously ex-
panded from a fresh CB unit and then cryopreserved for future
use. To date, 13 patients have been enrolled (see Table for pa-
tient/graft characteristics). Importantly, no infusional toxicities
have been observed and no serious adverse events have been at-
tributed to the expansion product. All (n 5 11) patients have en-
grafted, with 2 being too early post transplant to evaluate.
Median time to achieve an ANC of 100/ml and 500/ml was 11
(range 7 to 20) and 19 days (range 9 to 28), respectively as com-
pared to 19 (range 11 to 37) (p 5 0.0001) and 25 days (range 14
to 45) (p 5 0.004) in a concurrent cohort of patients receiving
ablative double CBT without the expanded cells. Donor(s)/host
chimerism studies were performed weekly from day 7 to 28 on
peripheral blood flow sorted into myeloid and lymphoid frac-
tions. Similar to our initial expansion trial using partially HLA-
matched expanded CB cells, early (day 7) myelomonocytic
(CD33 and CD14) recovery is almost entirely (98–100%) due
to cells arising from the expansion product. Cells derived from
the expansion product are no longer detected at day 14 in all
but 2 patients, which is similar to our previous trial in whichTable. Unit and Patient Characteristics Total Enrolled N5 13
PATIENT CHARACTERISTICS
Gender, No (%)
Male 7 (54%)
Female 6 (46%)
Age in years, median (range) 22 (5 to 45)
Weight in kilograms, median (range) 67 (22 to 84)
Diagnosis, No (%)
ALL 6 (46%)
AML 6 (46%)
MDS 1 (8%)
Follow-up in days, median (range) 180 (16 to 385)
UNIT CHARACTERISTICS
Number of Unmanipulated Donors, No (%)
1 2 (15%)
2 11 (85%)
HLA match unmanipulated Donors, No (%)*
4/6 8 (62%)
5/6 5 (38%)
Infused Cell Doses (pre-freeze)
(Continued )contribution to donor engraftment in any cell fraction from the
expanded unit was no longer detected by day 14 in half of the
patients and only two patients had persistence of the expanded
cells beyond day 21. Of note, the expanded cells have not been
associated with increased incidence or severity of acute GVHD
or with development of alloimmunization. All patients are alive;
one patient with relapsed disease at the start of conditioning is
being treated for post transplant relapse. These promising results
warrant evaluation in a randomized phase II study to assess clin-
ical efficacy of this non-HLA matched, off-the-shelf expansion
product.5
CMX001 FOR PREVENTION AND CONTROL OF CMV INFECTION IN CMV-
SEROPOSITIVE ALLOGENEIC STEM-CELL TRANSPLANT RECIPIENTS: A
PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
DOSE-ESCALATION TRIAL OF SAFETY, TOLERABILITY AND ANTIVIRAL
ACTIVITY
Marty, F.M.1,2, Winston, D.3, Rowley, S.D.4, Boeckh, M.5, Vance, E.6,
Papanicolaou, G.7, Robertson, A.8, Godkin, S.8, Painter, W.8 1Dana-
Farber Cancer Institute, Boston, MA; 2Brigham & Women’s Hospital,
Boston, MA; 3UCLA, Los Angeles, CA; 4Hackensack University Medical
Center, Hackensack, NJ; 5Fred Hutchinson Cancer Research Center, Seat-
tle, WA; 6Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Dallas, TX; 7Memorial Sloan-Kettering Cancer Center, New York,
NY; 8Chimerix, Inc., Durham, NC
Introduction: CMX001, an oral Lipid-Antiviral-Conjugate, gener-
ates high intracellular levels of cidofovir-diphosphate. CMX001 has
potent in vitro activity against dsDNA viruses including herpesvi-
ruses, adenoviruses, polyomaviruses, and orthopoxviruses. Patients
treated for these infections under individual EIND protocols experi-
enced reductions in virus loads following CMX001 treatment; how-
ever, controlled human safety and efficacy data were previously not
available.
Methods: This randomized, placebo-controlled, dose-escalation
study (CMX001-201) enrolled adult allogeneic CMV-seropositive
stem-cell transplant (SCT) recipients from 27 centers in USA. Pa-
tients, stratified post-engraftment by acute GVHD requiring sys-
temic glucocorticoid therapy or CMV viremia, were randomized
(3:1) to receive CMX001 or placebo into 5 sequential dose-escalating
cohorts. Subjects were treated either once weekly (QW) or twice
weekly (BIW) for 9 to 11 weeks until Week 13 post-transplant
with a 4 to 8 week safety follow-up period. Virology and safety as-
sessments were conducted weekly throughout the treatment period.
A DSMB reviewed safety data and directed CMX001 doses for each
cohort. Efficacy was measured by a composite endpoint of CMV dis-
ease or the appearance/progression of CMV viremia. Patients with
these endpoints discontinued study drug and received anti-CMV
treatment. This study was registered with ClinicalTrials.gov,
NCT00942305.S203
Table. CMX001-201 Study. Selected Baseline Characteristics and Efficacy/Safety Summary Data (blinded data, as of 30 September
2011)
Cohort 40mg/placebo QW 100mg/placebo QW 200mg/placebo (QW) 200mg/placebo BIW 100mg/placebo BIW
Patients enrolled, N 40 39 53 40 67
Evaluable patients, N 33 37 53 40 67
Baseline characteristics Percent of Evaluable Patients
Peripheral Stem-Cell recipients 85% 89% 72% 75% 87%
Bone Marrow Recipients 6% 3% 19% 20% 10%
Umbilical Cord-Blood Recipients 9% 8% 9% 5% 3%
ATG Administration during Conditioning 15% 14% 8% 15% 18%
Acute GVHD at baseline 18% 16% 11% 17% 9%
CMV PCR negative before dosing 70% 84% 76% 78% 84%
Completed treatment 36% 49% 43% 28% 57%
Efficacy Results
CMV Events to End of Treatment 42% 32% 19% 20% 18%
CMV DNAemia >1000 copies/mL 45% 27% 21% 18% 12%
Serious Adverse Events (SAE)
Patients with SAEs Leading to Discontinuation 21% 12% 9% 25% 6%
S204 CIBMTR Best Abstract Awards for Clinical ResearchResults: FromDec 2009 to Jun 2011, 239 subjects were enrolled into
the study. As of Oct 2011, all subjects had completed treatment and
final safety follow-up visits were underway. Blinded efficacy results
demonstrated a decrease of appearance or progression ofCMV infec-
tion or disease by day 100 post-SCT in subjects enrolled in higher
dose cohorts (see table). Dose-limiting diarrhea, often reported in
conjunction with GVHD, occurred in subjects treated in the highest
dose cohort (200mg BIW). Changes in renal and graft function were
similar across all cohorts during treatment and follow up. Final, un-
blinded safety and efficacy results of the study will be presented.
Conclusions: In this first Phase 2 trial of CMX001 ever conducted,
a reduction in new or progressive CMV infection occurred in alloge-
neic SCT patient cohorts receiving higher doses of CMX001
($200mg weekly). An increased incidence of diarrhea occurred in
patients receiving the highest dose of CMX001 (200mg BIW).
CMX001 has potential as a prophylactic antiviral agent in this pop-
ulation.
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OVERLAP SUBTYPE OF CHRONIC GVHD IS ASSOCIATED WITH ADVERSE
PROGNOSIS, FUNCTIONAL IMPAIRMENT, AND INFERIOR PATIENT RE-
PORTED OUTCOMES: A CHRONIC GVHD CONSORTIUM STUDY
Pidala, J.1, Vogelsang, G.2, Martin, P.3, Chai, X.3, Storer, B.3,
Pavletic, S.4, Weisdorf, D.5, Jagasia, M.6, Cutler, C.7, Palmer, J.8,
Jacobsohn, D.9, Arai, S.10, Lee, S.J.3 1Moffitt Cancer Center, Tampa,
FL; 2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
3Fred Hutchinson Cancer Research Center; 4National Cancer Institute;
5University of Minnesota; 6Vanderbilt University; 7Dana Farber Cancer
Institute; 8Medical College of Wisconsin; 9Children’s National Medical
Center; 10Stanford University
We examined whether overlap subtype of chronic GVHD was
associated with different prognosis, functional limitations, or pa-
tient reported outcomes compared to ‘‘classic’’ chronic GVHD.
Prospective data were collected from 427 patients from nine cen-
ters in an observational cohort study conducted by the ChronicGVHD Consortium. Patients were classified as overlap (n 5 352)
or classic chronic GVHD (n 5 75) based on organ involvement.
Among 352 overlap subjects, skin erythema or maculopapular
rash was present in 189 (54%), GI involvement in 129 (37%),
and liver involvement in 216 (62%); 198 (56%) met criteria with
acute features in only one organ, 126 (36%) with acute features
in two organs, and 28 (8%) with acute features in all three organs.
Overlap patients were more likely to be incident cases (59% vs
35%, p\.001), to have a shorter median time from transplant to
enrollment (11.9 months vs. 19.8 months, p 5 0.01), and to have
lower platelet count at chronic GVHD onset (p\ 0.001). Those
with overlap had significantly higher functional impairment by 2
minute walk test (p\0.001), higher symptom burden (Lee Chronic
GVHD Symptoms Scale) and lower Human Activity Profile scores
(p\0.001). Quality of life was similar, except overlap had worse SF-
36 social functioning. The median follow-up time after enrollment
for overlap patients was 17.1 months, and 19.0 months for classic
chronic GVHD patients. Two year OS was 77% and 94%, and
two year NRM was 20% and 3% for overlap and classic chronic
GVHD patients, respectively. Multivariable analyses in which over-
lap and classic were treated as time-varying covariates demon-
strated that overlap was associated with worse overall survival
(HR 2.1, 95% CI 1.1 – 4.7; p 5 0.03) and higher non-relapse mor-
tality (HR 2.8, 95% CI 1.2 – 8.3; p 5 0.02) than classic chronic
GVHD. Among other considered covariates in the OS analysis,
platelet count \ 100K (HR 3.4, 95% CI 1.9 – 6, p \ 0.001),
KPS \ 80 (HR 2.4, 95% CI 1.4 – 4.1, p 5 0.002), and severe
NIH global severity score (HR 5.1, 95% CI 1.5 – 32.1, p 5
0.03) were associated with OS. In the analysis of NRM, platelet
\ 100K (HR 3.1, 95% CI 1.6 – 5.9, p\ 0.001), and KPS\ 80
(HR 2.2, 95% CI 1.2 – 4.2, p 5 0.01) were associated with
NRM. These findings suggest that the presence of acute features
in patients with chronic GVHD is a marker for adverse prognosis,
greater functional impairment, and higher symptom burden. Fur-
ther study is needed to define optimal therapy for these patients.
